Neoadjuvant Atezolizumab, Trastuzumab, Pertuzumab,and Docetaxel Yields Acceptable pCR in ERBB2+ Breast Cancer

Article

The phase 1/2 Neo-PATH trial show promising pathological complete response rates and moderate toxicity in patients with stage III or III ERBB2-positive breast cancer when treated with pertuzumab, atezolizumab, trastuzumab, and docetaxel.

A promising pathological complete response (pCR) rate and tolerable toxicity profile were observed in patients with stage II or III ERBB2-positive breast cancer who were treated with a quadruplet regiment of atezolizumab (Tecentriq), docetazel, trastuzumab (Enhertu), and pertuzumab (Perjeta), according to data from the phase 1/2 Neo-PATH trial (NCT03881878) published in JAMA Oncology.

In a population of 41 patients, the overall pathologic complete response (pCR) rate was 61% (90% CI, 50%-71%). Residual cancer burden of class I response was observed in 12% of patients, class II in 19%, and class III in 4%. Those who had stage IIA cancer had a pCR rate in 69%, 70% for those with stage IIB disease, and 39% for those who had stage III disease. The clinical objective response rate was 94.0%. In patients who had hormone receptor (HR)–negative disease, the pCR rate was 77% compared with 44% for those with HR-positive disease. In patients who had PD-L1 expression, the pCR rate was 100% vs 53% in those with no expression.

“The neoadjuvant atezolizumab combination PATH demonstrated a pCR rate worth further investigation, with fewer hematologic toxic effects with prevalent long-acting filgrastim [Neupogen] support,” investigators of the study wrote.

A total of 67 patients enrolled across 6 institutions in Korea. By data cutoff, all patients had completed neoadjuvant treatment. During neoadjuvant treatment, 2 patients experienced progressive disease and the remaining patients undergoing curative surgery, of whom 42 underwent breast-conserving surgery and 23 received a mastectomy. In 64 patients, R0 resection was achieved.

Treatment with pertuzumab was administered intravenously at a dose of 840 mg in the first cycle and 420 mg, thereafter; atezolizumab at 1200 mg intravenously; docetaxel at 75 mg/m2 intravenously; and 600 mg of trastuzumab subcutaneously every 3 weeks then followed by curative surgery.

Patients had a median age of 52 years, 48% had positive HR expression, and 52% had negative HR expression. Overall, 73% of patients had clinical stage II breast cancer.

Overall, the most common hematologic adverse effect (AE) was neutropenia in 13% of patients, with 12% having grade 3 or higher events. Moreover, 8% of patients experienced febrile neutropenia. Non-hematologic AEs included myalgia (75%), alopecia (67%), neuropathy (58%), diarrhea (51%), fatigue (40%), nausea (33%), and mucositis (31%). A total of 8% of patients experienced grade 3 or higher AEs.

Frequent immune-related AEs included skin rash (64%), fever (30%), thyroid dysfunction (10%), pneumonitis (9%), hepatitis (3%), and encephalitis (2%). Immune-related AEs of grade 3 or higher occurred in 6% of patients and included rash, fever, hepatitis, and encephalitis in 1 patient each.

Treatment discontinuation or interruption of atezolizumab occurred in 10% of patients. Treatment was not interrupted for pertuzumab or trastuzumab. Serious AEs occurred in 21% of patients, with the most common being febrile neutropenia (6%), fever (5%), and other immune-related AEs (3%). No patients died during the neoadjuvant portion of the study.

Reference

Ahn HK, Sim SH, Suh KJ, et al. Response rate and safety of a neoadjuvant pertuzumab, atezolizumab, docetaxel, and trastuzumab regimen for patients with ERBB2-positive stage II/III breast cancer: the Neo-PATH phase 2 nonrandomized clinical trial. JAMA Oncol. Published online July 7, 2022. doi:10.1001/jamaoncol.2022.2310

Related Videos
A panel of 3 experts on lung cancer
A panel of 4 experts on multiple myeloma
Video 1 - 4 KOLs are featured in "Treating Patients Referred to Academic Centers for CAR T"
Video 1 - 4 KOLs are featured in "Identifying Potential Candidates for CAR T-Cell Therapy"
Beth Faiman, CNP, PhD, an expert on multiple myeloma
Jorge E. Cortes, MD, emphasizes proper communication between patients with chronic myeloid leukemia and their providers during the treatment course.
Dietary interventions or other medications may help mitigate diarrhea in patients who undergo therapy for chronic myeloid leukemia.
Considering notable adverse effects associated with treatment may be critical when selecting therapy options for those with CML.
Related Content